English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives:   The objective of this study was to quantify the risk of intracranial hypertension (ICH) with the intrauterine levonorgestrel (IUL) device Mirena ® .Methods:   We used the United States Food and Drug Administration’s Adverse Events Reporting System (FAERS) database to quantify a reporting odds ratio (ROR) for ICH and Mirena ® . We also conducted a retrospective cohort study using the IMS LifeLink ®  database, comparing the risk of two oral contraceptives ethinyl estradiol (EE) with Mirena ® . A Bayesian sensitivity analysis was performed to account for the effect of body mass index (BMI).Results:   The reported odds ratios (ORs) for ICH and papilledema with Mirena ®  were 1.78 (95% confidence interval [CI] 1.41–2.25) and 1.50 (95% CI 1.10–2.05), respectively. In the cohort study, the OR for ICH and EE-norgestimate and EE-norethindrone compared with Mirena ®  were 1.29 (95% CI 0.83–2.00) and 0.31 (95% CI 0.04–2.29), respectively. The presence of a strong confounder BMI did not affect the estimated OR (OR = 1.31, 95% CI 0.73–2.41 for EE-norgestimate; OR = 0.18, 95% CI 0.01–1.27 for EE-norethindrone).Conclusion:   We found a higher than expected number of reports of ICH with Mirena ®  in the FAERS database. We also found a similar risk of ICH with Mirena ®  compared with the oral contraceptive EE-norgestimate. The higher risk of ICH with EE-norethindrone, another oral contraceptive should be further investigated.

Risk of intracranial hypertension with intrauterine levonorgestrel